Cabergoline in the treatment of acromegaly: A study in 64 patients

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 2, 1998, Pages 374-378

  Abs, Roger ^a   Verhelst, Johan ^b   Maiter, Dominique ^c   Van Acker, Kristien ^a   Nobels, Frank ^d   Coolens, Jean Luc ^e   Mahler, Charles ^b   Beckers, Albert ^f  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b MIDDELHEIM HOSPITAL   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d OLV HOSPITAL   (Belgium)

^e Salvator Hospital   (Belgium)

^f UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; PROLACTIN; SOMATOMEDIN C;

ACROMEGALY; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; GROWTH HORMONE RELEASE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 0031792509     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.83.2.4556     Document Type: Article

References (24)

1. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. 1995 Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab. 80:3395-3402.
2. Kovacs K, Horvath E. 1987 Pathology of pituitary tumors. Endocrinol Metab Clin North Am. 16:529-551.
3. Bates AS, Van't Hoff W, Jones JM, Clayton RN. 1993 An audit of outcome of treatment in acromegaly. Q J Med. 86:293-299.
4. Melmed S. 1990 Acromegaly. N Engl J Med. 322:966-977.
5. Fahlbusch R, Honegger J, Buchfelder M. 1992 Surgical management of acromegaly. Endocrinol Metab Clin North Am. 21:669-692.
6. Eastman RC, Gordon P, Glatstein E, Roth J. 1992 Radiation therapy of acromegaly. Endocrinol Metab Clin North Am. 21:693-712.
7. Vance ML, Harris AG. 1991 Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicentre Acromegaly Study Group. Arch Intern Med. 151:1573-1578.
8. Ezzat S, Snyder FJ, Young WF, et al. 1992 Octreotide treatment of acromegaly. A randomised, multicentre study. Ann Intern Med. 117:711-718.
9. Caron P, Morange-Ramos I, Cogne M, Jaquet P. 1997 Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab. 82:18-22.
10. Kvistborg Fløgstad A, Halse J, Bakke S, et al. 1997 Sandostatin LAR in acromegalic patients: long term treatment. J Clin Endocrinol Metab. 82:23-28.
11. Chiodini PG, Cozzi R, Dallabonzana D, et al. 1987 Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. J Clin Endocrinol Metab. 64:447-453.
12. Halse J, Harris AG, Kvistborg A, et al. 1990 A randomised study of SMS 201-995 vs. bromocriptine treatment in acromegaly: clinical and biochemical effects. J Clin Endocrinol Metab. 70:1254-1261.
13. Webster J, Piscitelli G, Polli A, et al. 1994 A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhoea. N Engl J Med. 331:904-909.
14. Biller BMK, Molitch ME, Vance ML, et al. 1996 Treatment of prolactin-secreting macroadenoma with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab. 81:2338-2343.
15. Ferrari CI, Abs R, Bevan JS, et al. 1997 Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf). 46:409-413.
16. Lamberts SWJ, Klijn JGM, van Vroonhoven CCJ, Stefanko SZ, Liuzzi A. 1983 The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly. Acta Endocrinol (Copenh). 103:446-450.
17. Losa M, Oeckler R, Schopohl J, Muller OA, Alba-Lopez J, von Werder K. 1989 Evaluation of selective transsphenoidal adenomectomy by endocrinological testing and somatomedin-C measurements in acromegaly. J Neurosurg. 70:561-567.
18. Jaffe CA, Barkan AL. 1992 Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am. 121:713-735.
19. Chiodini PG, Attanasio R, Cozzi R, et al. 1993 CV 205-502 in acromegaly. Acta Endocrinol (Copenh). 128:389-393.
20. Plockinger O, Quabbe HJ. 1991 Evaluation of a repearable depot-bromocriptine preparation (Parlodel LAR) for the treatment of acromegaly. J Endocrinol Invest. 14.943-948.
21. Ferrari C, Paracchi A, Romano C, et al. 1988 Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin Endocrinol (Oxf). 29:467-476.
22. Colao A, Ferone D, Marzullo P, et al. 1997 Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab. 82:518-523.
23. Jackson SNJ, Fowler J, Howlett TA. 1997 Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin Endocrinol (Oxf.) 46:745-749.
24. Frans E, Dom R, Demedts M. 1992 Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline. Eur Respir J. 5:263-265.